Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (NASDAQ: QDEL) is a global leader in diagnostic healthcare solutions, specializing in rapid testing technologies that inform critical clinical decisions. This news hub provides investors and healthcare professionals with timely updates on the company's innovations, regulatory milestones, and market developments.
Access official press releases and curated analysis covering financial results, product launches, strategic partnerships, and advancements in immunoassay or molecular diagnostic technologies. Our repository simplifies tracking of QDEL's contributions to transfusion safety, infectious disease detection, and clinical chemistry solutions across 100+ countries.
Bookmark this page for direct access to essential updates about FDA clearances, international expansion efforts, and research breakthroughs. All content is sourced from verified channels to ensure accuracy in reporting on this NASDAQ-listed innovator's role in shaping diagnostic medicine.
QuidelOrtho (Nasdaq: QDEL), a global provider of in-vitro diagnostic technologies, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day to discuss the results.
Investors can access the call through the company's website at ir.quidelortho.com or by phone using the following dial-in numbers:
- Domestic: 833-470-1428
- International: +1 929-526-1599
- Conference ID: 170283
Presentation materials will be available on the company's Investor Relations page during the call, and a replay will be accessible shortly after the event.
QuidelOrtho (Nasdaq: QDEL) has launched the Results Manager™ System, an advanced informatics solution designed for laboratories in community hospitals and point-of-care settings. The system offers key features including:
- Real-time quality monitoring for instruments and assays
- Operational efficiency through auto-verification and simplified rule-writing
- Seamless connectivity with multiple instruments
- Enhanced clinical decision-making capabilities
- Cost-effective deployment with easy installation
The system addresses critical challenges such as rising test volumes, staffing shortages, and increasing complexity while maintaining focus on patient care. Early trial users, including Lab Manager Steve Mulliner from MB Healthcare Services , reported positive feedback on the system's intuitive interface and efficiency improvements. QuidelOrtho is now launching the Results Manager system worldwide, with availability varying by country.
QuidelOrtho (NASDAQ: QDEL), a global provider of innovative in-vitro diagnostic technologies, has announced its participation in the 46th Annual Raymond James Institutional Investor Conference. The company's management team will deliver a presentation on Wednesday, March 5, 2025, at 8:40 a.m. ET / 5:40 a.m. PT.
Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events & Presentations' section on QuidelOrtho's Investor Relations website at https://ir.quidelortho.com. The company specializes in diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine.
QuidelOrtho (QDEL) reported Q4 2024 revenue of $708 million, down from $743 million year-over-year, primarily due to lower COVID-19 and influenza revenue. Q4 non-respiratory revenue was $565 million, while respiratory revenue decreased 18% to $143 million.
Full-year 2024 revenue reached $2.8 billion, compared to $3.0 billion in 2023. The company reported a GAAP net loss of $2.03 billion for 2024, including a $1.82 billion non-cash goodwill impairment charge. Adjusted EBITDA was $543 million with a 19.5% margin, down from $723 million and 24% margin in 2023.
Looking ahead, QuidelOrtho issued 2025 guidance projecting revenue between $2.60-$2.81 billion, adjusted EBITDA of $575-$615 million, and adjusted EBITDA margin of 22%. The company expects a $55 million negative impact from foreign currency exchange based on January 2025 rates.
QuidelOrtho (NASDAQ: QDEL) has announced preliminary unaudited revenue for Q4 2024, with expected total reported revenues ranging between $702 million to $707 million, aligning with previously announced guidance. The breakdown includes:
- Non-respiratory revenue: $561-563 million
- Respiratory revenue: $141-143 million
The company had a transformative 2024, focusing on high-growth opportunities, leadership realignment, and implementing cost-saving measures. QuidelOrtho plans to release complete Q4 and full-year 2024 financial results on February 12, 2025, followed by a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
QuidelOrtho (QDEL), a global provider of in-vitro diagnostic technologies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST / 10:30 a.m. EST. Investors and interested parties can access both the live webcast and replay through the 'Events & Presentations' section on QuidelOrtho's investor relations website.
QuidelOrtho (QDEL) has announced the pricing of a secondary offering where Carlyle Partners VI Cayman Holdings will sell 8,260,183 shares of common stock. Goldman Sachs & Co. is serving as the sole underwriter for the offering, which is expected to close on November 21, 2024. QuidelOrtho will not receive any proceeds from this transaction as all proceeds will go to the selling stockholder. The offering is being conducted through an effective shelf registration statement filed with the SEC.
QuidelOrtho (QDEL) announced a secondary offering where Carlyle Partners VI Cayman Holdings will sell 8,260,183 shares of common stock. The last reported stock price was $38.58 per share on November 19, 2024. Goldman Sachs & Co. is the sole underwriter. Following the offering, Carlyle will exit its position entirely, terminating their Principal Stockholders Agreement and losing board nomination rights. QuidelOrtho will not receive any proceeds from this offering as all proceeds go to the selling stockholder.
QuidelOrtho reported its Q3 2024 financial results, highlighting a total revenue of $727 million, down from $744 million the previous year, mainly due to higher COVID-19 and influenza revenues in the prior period. GAAP net loss was $20 million compared to $13 million last year, with a GAAP diluted loss per share of ($0.30) versus ($0.19). GAAP operating income was $15 million, down from $26 million, and GAAP operating margin was 2%, compared to 4% previously. Adjusted EPS was $0.85, slightly down from $0.90. Adjusted EBITDA was $171 million, up from $169 million, with a margin of 23.5% compared to 22.7%.
The company reinstated 2024 financial guidance, projecting total revenues of $2.75-$2.80 billion, adjusted EBITDA of $530-$550 million, and adjusted EPS of $1.69-$1.91. QuidelOrtho also emphasized ongoing cost-saving initiatives and leadership enhancements to drive future growth.
QuidelOrtho (Nasdaq: QDEL), a global provider of in vitro diagnostic technologies, has announced its participation in three major investor conferences. The company will engage in fireside chats at the UBS Global Healthcare Conference on November 12, 2024, at 2:00 p.m. ET in Rancho Palos Verdes, the Citi 2024 Global Healthcare Conference on December 4, 2024, at 1:00 p.m. ET in Miami, and the Evercore ISI 7th Annual HealthConX Conference on December 5, 2024, at 10:00 a.m. ET in Coral Gables. Live webcasts and replays will be available through QuidelOrtho's investor relations website.